NUR 514 Week 5 CLC Assignment

NUR 514 Week 5 CLC Assignment, When Patient Advocacy Meets Policy - Lobbying for Healthcare Change Presentation. CLC - WHEN PATIENT ADVOCACY MEETS POLICY: LOBBYING FOR HEALTH CARE CHANGE PRESENTATION INTRODUCTION: PRESCRIPTION DRUGS PRICING • In the United States, spending on prescription drugs reached approximately $457 billion as of 2015, which accounts for 17% of the total cost for personal healthcare services (Cohen, 2016). • Insurance companies, on the other hand, are shifting this high prescription drug costs to consumers in different forms such as high insurance premiums, co-payments, and deductibles. • Consequently, the high cost has made it hard for most consumers to acquire essential drugs. • Nearly 1 out of 10 Americans adults reported not taking their medication last year as a way of saving money. • The out of control drug prices has posed a great challenge to every America, especially in Texas. PRESCRIPTION DRUGS PRICING IN RELATION TO NURSING PRACTICE • The main objective of an advanced registered nurse leader is focused on enhancing wellness and preventive healthcare as per the consumer demands (Patel, & Rushefsky, 2014). • The increasing cost of prescription drugs has however crippled this objective as nurses are unable to enhance a cost-effective, high-quality care provision. • For instance, medications, especially for the treatment and prevention of chronic illness have a substantial effect in reducing morbidity and mortality rates. • Medication has great value only if the consumer has access to it. Failure to access essential drugs put no value to medication in the first place, hence undermining the patient’s health and the entire care process. IMPLICATIONS IF LOBBYING EFFORTS DO NOT SUCCEED To the consumer: • High rates of bankruptcies • Abandoned or compromised treatments • Untreated infections that might render the patient prone to chronic illnesses like heart attack • Poor quality of life • Increased morbidity and mortality rates IMPLICATIONS IF LOBBYING EFFORTS DO NOT SUCCEED To the healthcare system: • Shortage of drugs in healthcare settings • Increased number of counterfeit drugs • Lack of transparency • Reduced quality of health provided IMPLICATIONS IF LOBBYING EFFORTS DO NOT SUCCEED • Private interests seeking to influence government decisions, legislation or the award of contracts is part of the policy-making process in modern democracies. Lobbying can improve government decisions by providing valuable insights and data. IMPLICATIONS IF LOBBYING EFFORTS DO NOT SUCCEED IF CHECK LIST IN PLACE • 1. Do all stakeholders have fair and equitable access to the development and implementation of public policies? 2. Do rules and guidelines on lobbying respect the socio-political and administrative context? 3. Are the rules and guidelines on lobbying consistent with the wider policy and regulatory frameworks? 4. Are the terms “lobbying” and “lobbyist” clearly defined in the rules and guidelines on lobbying? 5. Is sufficient information on lobbying activities publicly available? 6. Can lobbying activities be scrutinized by stakeholders? 7. Are there clear rules and guidelines of conduct for public officials on how to engage with lobbyists? 8. Do lobbyists comply with standards of professionalism and transparency? 9. Is there a coherent spectrum of strategies and practices to ensure compliance with rules on lobbying? 10. Is the functioning of rules and guidelines on lobbying periodically reviewed to ensure compliance 2018 ENACTED STATE LAWS AFFECTING PHARMACEUTICAL COSTS, PRICING AND P• InAtheYpaMst yeEar, NthereThas been increased interest and legislative activity about the pricing, payment and costs associated with prescription drugs. States have enacted a diverse set of policy initiatives related to these topics in 2018, with a total of 94 signed bills in 39 states. This search is based on the following database filters on NCSL’s Statewide Prescription Drug Database – Topics: Cost Sharing and Deductibles, Pharmaceutical Pricing and Payment, Rx Medicaid Use and Cost, and Pharmacy Benefit Managers. • In the past year, there has been increased interest and legislative activity about the pricing, payment and costs associated with prescription drugs. States have enacted a diverse set of policy initiatives related to these topics in 2018, with a total of 94 signed bills in 39 states. This search is based on the following database filters on NCSL’s Statewide Prescription Drug Database – Topics: Cost Sharing and Deductibles, Pharmaceutical Pricing and Payment, Rx Medicaid Use and Cost, and Pharmacy Benefit Managers. • Concerns health plan coverage and access to reproductive health care. Requires health plans provide coverage for all contraceptive drugs, devices, and other products and voluntary sterilization procedures. A health plan that provides coverage for maternity care or services must also provide a covered person with substantially equivalent coverage to permit the abortion of a pregnancy. The Interagency Coordinating Council on Health Disparities shall provide a literature review of disparities in access to reproductive health care and make recommendations to the governor and relevant committees this bill implemented in WASHINGTON in 2018 WAS6219 METHODS TO TRACK A BILL AND PARTICIPATE IN LOBBYING EFFORTS. 1. Understanding the legislative process. 2. Introduce a bill 3. Refer the bill to an appropriate committee 4.Review the bill in committee or subcommittee 5.Mark up the bill 6. Report the bill 7. Debate the bill and vote on the bill METHODS TO TRACK A BILL AND PARTICIPATE IN LOBBYING EFFORTS. • Repeat the process in the other chamber of congress • Allow the president to make a decision SHOULD THIS BILL PASS ? • This Bipartisan Bill is an attempt to reign in drug prices in Washington State, which has a tremendous affect on patient compliance and ultimately wellness. • It is our groups stance that this type of mandate is necessary to assist in health , safety and wellness of our patients and their families, and thus agree with the recent passing of this bill. SENATE BILL 5251- WASHINGTON AMENDING RCW 74.09.215 CONT. • Section 7- Manufacturing a new drug application • Section 8- Annual drug list • Section 9- Manufactures drug price reporting • Section 10- Enforcement • Section 11- Rule making • Section 12- Medicaid fraud penalty • Section 13- SENATE BILL 5251- WASHINGTON AMENDING RCW 74.09.215 • This Senate bill has 13 sections to include the following : • Section 1- Findings • Section 2-Definitions • Section 3- Issuer reporting • Section 4- Prescription benefits manager • Section 5- Prescription services administration • Section 6- Data collection and reporting PROPOSED LEGISLATION BIPARTISAN BILL • Senate Bill 5251/ House Bill 1224 AN ACT Relating to prescription drug cost transparency; reenacting and amending RCW 74.09.215; adding a new chapter to Title 43 RCW; creating new sections; and prescribing penalties. REFERENCES • Patel, K., & Rushefsky, M. E. (2014). Healthcare politics and policy in America. Armonk, New York: M.E. Sharpe. • Parker-Lue, S., Santoro, M., & Koski, G. (January 01, 2015). The Ethics and Economics of Pharmaceutical Pricing. Annual Review of Pharmacology and Toxicology, 55, 191- 206. • Ghosh, A., Simon, K., & Sommers, B. D. (January 01, 2019). The Effect of Health Insurance on Prescription Drug Use Among Low-Income Adults: Evidence from Recent Medicaid Expansions. Journal of Health Economics, 63, 64-80. • Cohen, S. S. (January 01, 2016). Soaring Prescription Drug Prices. Policy, Politics & Nursing Practice, 17, 3, 115-117.